GLP-1 manufacturer savings calculator

What the Manufacturer savings does

This page answers one question: for a given GLP-1 medication and your insurance situation, which manufacturer savings program gives you the lowest published out-of-pocket cost? You pick one of four drugs (Mounjaro, Ozempic, Wegovy, or Zepbound) and one of four coverage statuses (commercial insurance, Medicare, Medicaid, or uninsured/cash-pay), and the tool shows every matching program along with the cheapest one.

It is a lookup against a fixed, hand-maintained list of eight real programs from Eli Lilly and Novo Nordisk: LillyDirect self-pay vials, the Lilly Savings Cards for Mounjaro and Zepbound, NovoCare and WeGoTogether savings for Ozempic and Wegovy, NovoCare Direct cash Wegovy, and the Lilly Cares and Novo Nordisk patient assistance programs. There is no model, no prediction, and no live pricing feed. Each program carries a fixed monthly figure the manufacturer has published, and the tool simply filters by drug and coverage, then sorts to find the smallest number.

The result is a shortlist with links to each manufacturer's own enrollment page. It is a starting map of what exists, not a quote, an application, or medical advice. The site is affiliate-supported and earns nothing from these manufacturer programs.

How to read your result

The four stat tiles read left to right as a before-and-after. "List price" is the manufacturer cash list price the tool stores for your drug (Mounjaro $1,086, Ozempic $968, Wegovy $1,349, Zepbound $1,086 per month). "Best available cost" is the lowest monthly figure among the programs you qualify for. "Monthly savings" and "annual savings" are just list price minus that best figure, times twelve for the year. These are arithmetic on stored numbers, not a bill you will receive.

Below the tiles, "Eligible programs" lists every match with its own monthly figure, a plain-language note on the catch (annual caps, dose limits, income limits), and a link to the manufacturer. A $0 figure means a patient assistance program that supplies the drug free to those who qualify, not that it costs nothing to everyone.

If you see "No manufacturer programs match," that is the tool telling you a real gap. Medicaid returns nothing because federal anti-kickback rules bar manufacturer copay cards for Medicaid recipients. Medicare returns only patient assistance programs, since copay cards are also off-limits there. Treat an empty result as a signal to ask a prescriber or pharmacist about other routes, not as a dead end.

What the result is based on

Every number on this page comes from the tool's own hardcoded table, not a live query. It stores four cash list prices and eight programs, each with a fixed monthly cost, an eligibility list (which coverage types qualify), and which drugs it applies to. The savings math is a single subtraction: stored list price minus the lowest qualifying program cost.

Notable stored details you can act on: the Lilly and Novo commercial savings cards land eligible commercially-insured patients as low as $25 per month; LillyDirect self-pay Zepbound starter vials are listed at $349; NovoCare Direct cash Wegovy at $499; and both patient assistance programs use a 400% of federal poverty line income limit. The tool itself flags all figures as real published offerings as of 2026, subject to change, to be verified on the manufacturer's site before enrolling.

What it cannot tell you

• It only knows four drugs and eight programs. Other GLP-1 or diabetes medications, compounded versions, and any regional or pharmacy-specific discount are outside its table entirely.
• It does not read your plan. The $25 savings-card figures assume your commercial insurance actually covers the drug; if your plan excludes it, your real cost can jump to the uninsured cash figure instead, and the tool cannot tell which case you are in.
• List prices and program amounts are stored snapshots labeled 'as of 2026.' Manufacturers change caps, prices, and eligibility without notice, so a figure here can be stale. The tool tells you to verify on the manufacturer page for this reason.
• Patient assistance programs show $0, but that only applies to people who clear the 400% federal-poverty-line income test and other requirements the tool does not check. It cannot confirm you qualify.
• Annual savings is simply monthly savings times twelve. It ignores per-fill and yearly benefit caps (for example the Mounjaro card's roughly $1,973 annual maximum), dose changes, and any month you fall off the program, so the yearly figure is an optimistic ceiling.
• It is not medical or financial advice and does not account for what a specific prescriber, pharmacy, or telehealth provider will actually charge you.